3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Leukemia, Myelomonocytic, Chronic
2
Anemia, Refractory, with Excess of Blasts
2
Wilms Tumor
1
Uveal Melanoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligodendroglioma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Hepatoblastoma
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
GATA2 Deficiency
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Anemia, Refractory
1
Interventions
Gemcitabine
29
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
17
Specimen Handling
16
Mitomycin
10
enfortumab vedotin
9
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Vorinostat
×
90 days
×
Clear all
No trials found.